FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
Stockhead on MSN
Health Check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
This stock is making its shareholders smile on Tuesday. Let's find out why. The post Why is this ASX 200 share charging 7% higher today? appeared first on The Motley Fool Australia.
Accounting for 55.6% of the total, salaries and benefits were the biggest expense at $11.16 billion, up 6.45% from 2024. Mayo ...
LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...
The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...
It’s been nearly 60 years since Doug Chamberlain, a Marine veteran and later Wyoming legislator, came home from Vietnam. The war changed him, and ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results